Table 2.

Molecular and clinical characteristics

PIK3CAOtherAgeSexTobacco usePack yearsStageTreatment neoadjuvant or first-lineSurvival
E542KKRAS61FCurrent30IIBCisplatin & Doce17+
E542KBRAF78FFormer30IAGefitinib15
E545KKRAS77FFormer20IBCarbo & Doce3
E545K70FNever0IIA5+
E545KKRAS65FCurrent45IIIA7
E545K74FFormer40IIIBCarbo & Pacli & RT27
E545K50MCurrent70IVCarbo & Pacli21
E545KEGFR57MCurrent50IVCarbo & Peme11
E545KKRAS74FFormer50IIIBRT10
E545KKRAS65FCurrent40IVCarbo & Peme6
E545KKRAS71MFormer55IVCisplatin & Doce & B16
E545KKRAS64FFormer15IVUnknown13
H1047LKRAS66MFormer30IA3+
H1047L34FFormer10IVCisplatin & Peme31
H1047LEGFR61MNever0IVErlotinib21a
H1047R71MFormer45IACarbo & Pacli & RT1+
H1047R68FNever0IA2+
H1047RKRAS38MNever0IIACisplatin & Doce & B4
H1047REGFR57FNever0IVErlotinib12a
H1047RMEK169MFormer100IVPeme & Pacli & B6a
H1047RKRAS76MNever0IVCarbo & Peme9
H1047R64FNever0IVPeme & Pacli & B23a
H1047RALK73FNever0IVErlotinib23

NOTE: Survival, disease free in early-stage patients (I–IIIA) and overall in advanced stage patients (IIIB/IV).

Abbreviations: Pacli, paclitaxel; Carbo, carboplatin; B, bevacizumab; Peme, pemetrexed; Doce, docetaxel; RT, radiotherapy; + disease free.

  • aAlive with disease.